SEQUENCEFOUR
DEAD

Serial Number

97694840

Owner

CureVac RNA Printer GmbH

Attorney

Jennifer Fraser

Filing Date

Nov 28, 2022

Add to watchlist:

No watchlists yet
View on USPTO

SEQUENCEFOUR Trademark

Serial Number: 97694840

SEQUENCEFOUR is a trademark filed by CureVac RNA Printer GmbH on November 28, 2022. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 7 (Machinery), Class 9 (Computers & Electronics), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

CureVac RNA Printer GmbH

Friedrich-Miescher-Str. 15
Tübingen 72076 , DE

Entity Type: 99

CUREVAC MANUFACTURING GMBH

FRIEDRICH-MIESCHER-STRASSE 15
TUBINGEN 72076 , DE

Entity Type: 27

Trademark Details

Filing Date

November 28, 2022

Registration Date

Not Registered

Published for Opposition

January 21, 2025

Goods & Services

Scientific and technological services and research, in particular for identification, testing and characterisation of biological molecules; pre-clinical and clinical testing of macromolecules

Custom synthesis of chemical compounds, namely, biological macromolecules, to the order and specifications of others

Chemicals and biomolecules, namely, biological macromolecules, for industrial or scientific purposes other than for medical or veterinary purposes; Reagents for research purposes; Reagents for use in scientific apparatus for chemical or biological analysis and/or synthesis

Laboratory apparatus and instruments, namely, pre-packed columns for use in chemical synthesis; mobile laboratory robots with artificial intelligence for use in scientific, diagnostic and pharmaceutical research and for use in pharmaceutical production and laboratory automation; mobile device for the synthesis of macromolecules, namely, for therapeutic and preventive treatment of tumor diseases, infectious diseases, autoimmune disorders and allergies, for treatment of inherited genetic diseases or for protein or enzyme replacement therapy, and for treatment of neurological, neuromuscular, neurodegenerative and cardiovascular diseases, and for treatment of metabolic disorders; Mobile production station of biological macromolecules, namely, for therapeutic and preventive treatment of tumor diseases, infectious diseases, autoimmune disorders and allergies, for treatment of inherited genetic diseases or for protein or enzyme replacement therapy, and for treatment of neurological, neuromuscular, neurodegenerative and cardiovascular diseases, and for treatment of metabolic disorders; bioreactors for growing cells

Chemical preparations for medical use, namely, biological macromolecules, namely, for therapeutic and preventive treatment of tumor diseases, infectious diseases, autoimmune disorders and allergies, for treatment of inherited genetic diseases or for protein or enzyme replacement therapy, and for treatment of neurological, neuromuscular, neurodegenerative and cardiovascular diseases, and for treatment of metabolic disorders; Pharmaceutical and veterinary preparations for medical and veterinary use; Pharmaceuticals and medicines based on biological macromolecules for the treatment of neurological, neuromuscular, neurodegenerative and cardiovascular diseases, for treatment or prevention of infectious diseases, allergies, autoimmune disorders and tumor diseases, for treatment of metabolic disorders and for treatment of inherited genetic diseases or for protein or enzyme replacement therapy; Gene therapeutic preparations; Dietetic substances adapted for medical use, in particular substances for food supplements; Vaccines

Machines for use in chemical or biopharmaceutical industry, namely for the synthesis of macromolecules; Bioreactors for the synthesis of macromolecules; Filling machines, in particular for use for filling biopharmaceutical compositions into containers; Industrial robots

Medical and veterinary services, in particular for therapeutic and preventive treatment of tumour diseases, infectious diseases, autoimmune disorders and allergies, for treatment of inherited genetic diseases or for protein or enzyme replacement therapy, and for treatment of neurological, neuromuscular, neurodegenerative and cardiovascular diseases, and for treatment of metabolic disorders; Vaccination

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Oct 21, 2025 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Oct 20, 2025 ABN6
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Mar 18, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 21, 2025 NPUB
PUBLISHED FOR OPPOSITION
Jan 21, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 15, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 30, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 29, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 29, 2024 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Dec 29, 2024 ERSI
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Dec 4, 2024 ASGN
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Oct 31, 2024 GNS2
INQUIRY TO SUSPENSION E-MAILED
Oct 31, 2024 GNSI
SUSPENSION INQUIRY WRITTEN
Oct 31, 2024 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Oct 29, 2024 RCCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Dec 12, 2023 GNS3
LETTER OF SUSPENSION E-MAILED
Dec 12, 2023 GNSL
SUSPENSION LETTER WRITTEN
Dec 12, 2023 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 12, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 11, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 11, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 9, 2023 GNRN
NON-FINAL ACTION E-MAILED
Sep 9, 2023 GNRT
NON-FINAL ACTION WRITTEN
Sep 9, 2023 CNRT
ASSIGNED TO EXAMINER
Sep 6, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 21, 2022 NWOS
NEW APPLICATION ENTERED
Dec 1, 2022 NWAP